Gastrointestinal Elimination of Perfluorinated Compounds Using Cholestyramine and Chlorella pyrenoidosa.
Gastrointestinal Elimination of Perfluorinated Compounds Using Cholestyramine and Chlorella pyrenoidosa.
复制标题
DOI：
10.1155/2013/657849
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Birkholz D
中科院分区：
文献类型：
--
作者：
Genuis SJ;Curtis L;Birkholz D
背景虽然全氟化合物（PFC）是具有许多应用的常用合成化合物家族，但部分由于肠肝再循环和肾小管重吸收，一些PFC在人体内保持持久性。随着人们越来越认识到全氟化学品的生物累积性对人类健康的潜在危害，为预防或克服疾病，采取干预措施促进消除这些有毒物质是受欢迎的。迄今为止，对加速人类清除全氟化学品的方法进行的研究很少。方法.为了测试可能的口服治疗，以加速PFC消除，一组PFC水平升高的个体用消胆胺（CSM）治疗，休息后，随后用蛋白核小球藻（CP）治疗。在（i）任何治疗前，（ii）CSM治疗期间，和（iii）CP治疗期间，采集所有参与者的粪便样本。结果CSM治疗后，在所有粪便中发现了显著水平的三种不同的PFC，而治疗前的水平大多无法检测到。经口服CP处理后，在每个测试样本中均观察到所有PFC的不可检测或非常低的水平。结论CSM似乎有助于消除一些常见的PFC，并可能在临床管理积累的PFC患者中发挥一定作用。
Background. While perfluorinated compounds (PFCs) are a family of commonly used synthetic compounds with many applications, some PFCs remain persistent within the human body due, in part, to enterohepatic recirculation and renal tubular reabsorption. With increasing recognition of potential harm to human health associated with PFC bioaccumulation, interventions to facilitate elimination of these toxicants are welcome in order to potentially preclude or overcome illness. Minimal research has been undertaken thus far on methods to accelerate human clearance of PFCs. Methods. To test for possible oral treatments to hasten PFC elimination, a group of individuals with elevated PFC levels was treated with cholestyramine (CSM) and, after a break, was subsequently treated with Chlorella pyrenoidosa (CP). Stool samples were collected from all participants (i) prior to any treatment, (ii) during treatment with CSM, and (iii) during treatment with CP. Results. With CSM treatment, significant levels of three distinct PFCs were found in all stools, while levels were mostly undetectable prior to treatment. Following treatment with oral CP, undetectable or very low levels of all PFCs were noted in each sample tested. Conclusion. CSM appears to facilitate elimination of some common PFCs and may have some role in the clinical management of patients with accrued PFCs.